-
Je něco špatně v tomto záznamu ?
Delivery of doxorubicin using protein nanocarriers
Simona Dostálová, Dita Műnzová, Markéta Vaculovičová, René Kizek
Jazyk angličtina Země Česko
Typ dokumentu práce podpořená grantem, srovnávací studie
NLK
Open Access Digital Library
od 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2014 do 2015
- Klíčová slova
- enkapsulace léčiv,
- MeSH
- apoferritiny MeSH
- bakteriofág lambda MeSH
- doxorubicin * MeSH
- fluorescence MeSH
- nanomedicína MeSH
- nanostruktury MeSH
- systémy cílené aplikace léků * MeSH
- Publikační typ
- práce podpořená grantem MeSH
- srovnávací studie MeSH
Anthracycline antibiotic drugs are widely used in treatment of many patients with cancer. First anthracycline drug, daunomycin (or daunorubicin) was found in a number of different wild type strains of Streptomyces. However, in cancer treatment the most commonly used anthracycline drug is doxorubicin (DOX) or one of its 2000 known analogs1. DOX is used in treatment of many different types of cancer such as neuroblastomas, leukaemia, lymphomas or breast, testicle, ovarian, lung, bladder, thyroid gland or head and neck carcinomas. Although it is so widely used, many side effects have been observed in patients such as sores in mouth and on lips, darkening of palms and nails, unusual bleeding and bruising, nausea and vomiting, and life-threatening cardiotoxicity 2. To eliminate the negative side effects of cancer treatment, researchers are trying to find either new analogs of DOX which are non-toxic for healthy cells or new way to deliver DOX directly into the cancer cells. For targeted delivery, it is possible to administer the drug directly into solid tumor. However, non-solid tumors or tumors with unknown location in patient’s body require encapsulation of DOX in suitable nanocarrier. Liposomal form of DOX is already being sold under the trade name Myocet 3. For enhanced biocompatibility, the liposomes were modified with polyethylene glycol under the trade name Doxil 4. Protein based natural nanocarriers in comparison with artificial nanocarriers seem to be more suitable for delivery of the drugs in patient’s body because of their lower immune response. The protein nanocarriers are usually self-assembled and can either be protein cages, viral capsids or virus-like particles 5. In this work, we compared two types of protein nanocarriers – phage λ and apoferritin, by their ability to encapsulate anthracycline drug doxorubicine. The encapsulation was verified by fluorescence of doxorubicin after the removal of free, non-encapsulated doxorubicin by dialysis.
Central European Institute of Technology Brno University of Technology
Department of Chemistry and Biochemistry Mendel University in Brno
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15013345
- 003
- CZ-PrNML
- 005
- 20150610135807.0
- 007
- ta
- 008
- 150416s2014 xr d f 000 0|eng||
- 009
- AR
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Dostálová, Simona $7 _AN082240 $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology
- 245 10
- $a Delivery of doxorubicin using protein nanocarriers / $c Simona Dostálová, Dita Műnzová, Markéta Vaculovičová, René Kizek
- 504 __
- $a Literatura
- 520 3_
- $a Anthracycline antibiotic drugs are widely used in treatment of many patients with cancer. First anthracycline drug, daunomycin (or daunorubicin) was found in a number of different wild type strains of Streptomyces. However, in cancer treatment the most commonly used anthracycline drug is doxorubicin (DOX) or one of its 2000 known analogs1. DOX is used in treatment of many different types of cancer such as neuroblastomas, leukaemia, lymphomas or breast, testicle, ovarian, lung, bladder, thyroid gland or head and neck carcinomas. Although it is so widely used, many side effects have been observed in patients such as sores in mouth and on lips, darkening of palms and nails, unusual bleeding and bruising, nausea and vomiting, and life-threatening cardiotoxicity 2. To eliminate the negative side effects of cancer treatment, researchers are trying to find either new analogs of DOX which are non-toxic for healthy cells or new way to deliver DOX directly into the cancer cells. For targeted delivery, it is possible to administer the drug directly into solid tumor. However, non-solid tumors or tumors with unknown location in patient’s body require encapsulation of DOX in suitable nanocarrier. Liposomal form of DOX is already being sold under the trade name Myocet 3. For enhanced biocompatibility, the liposomes were modified with polyethylene glycol under the trade name Doxil 4. Protein based natural nanocarriers in comparison with artificial nanocarriers seem to be more suitable for delivery of the drugs in patient’s body because of their lower immune response. The protein nanocarriers are usually self-assembled and can either be protein cages, viral capsids or virus-like particles 5. In this work, we compared two types of protein nanocarriers – phage λ and apoferritin, by their ability to encapsulate anthracycline drug doxorubicine. The encapsulation was verified by fluorescence of doxorubicin after the removal of free, non-encapsulated doxorubicin by dialysis.
- 650 12
- $a systémy cílené aplikace léků $7 D016503
- 650 12
- $a doxorubicin $7 D004317
- 650 _2
- $a apoferritiny $7 D001052
- 650 _2
- $a bakteriofág lambda $7 D010582
- 650 _2
- $a nanostruktury $7 D049329
- 650 _2
- $a nanomedicína $7 D050997
- 650 _2
- $a fluorescence $7 D005453
- 653 00
- $a enkapsulace léčiv
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Münzová, Dita $7 _AN082246 $u Department of Chemistry and Biochemistry, Mendel University in Brno
- 700 1_
- $a Vaculovičová, Markéta $7 _AN082228 $u Department of Chemistry and Biochemistry, Mendel University in Brno;Central European Institute of Technology, Brno University of Technology
- 700 1_
- $a Kizek, René, $d 1972- $7 jn20001005291 $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology
- 773 0_
- $t Journal of Metallomics and Nanotechnologies $x 2336-3940 $g Roč. 1, č. 4 (2014), s. 34-38 $w MED00185603
- 856 41
- $u http://web2.mendelu.cz/af_239_nanotech/J_Met_Nano/0414/pdf/JMN4-00-07.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2733 $c 398 $y 4 $z 0
- 990 __
- $a 20150415135905 $b ABA008
- 991 __
- $a 20150610140154 $b ABA008
- 999 __
- $a ok $b bmc $g 1070972 $s 896217
- BAS __
- $a 3
- BMC __
- $a 2014 $b 1 $c 4 $d 34-38 $i 2336-3940 $m Journal of Metallomics and Nanotechnologies $x MED00185603
- LZP __
- $c NLK188 $d 20150610 $a NLK 2015-15/pk